New drug aims to shrink heart attack damage in early trial
NCT ID NCT07091929
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This early-stage study tested a new medicine called SGC001 in 38 people having a heart attack procedure. The goal was to see if it is safe and could reduce heart muscle damage and inflammation. Participants received either the drug or a placebo by IV once. The drug is not yet approved anywhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTERIOR MYOCARDIAL INFARCTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Anzhen Hospital Capital Medical University
Beijing, Beijing Municipality, 100013, China
-
Linfen Central Hospital
Linfen, Shanxi, 041099, China
-
Teda International Cardiovascular Hospital
Tianjin, Tianjin Municipality, 300457, China
-
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150086, China
Conditions
Explore the condition pages connected to this study.